Corresponding research: Research led by Yoshihiro Kawaoka, a virologist at the University of Wisconsin School of Veterinary Medicine and the University of Tokyo, indicated that other antivirals such as Paxlovid, remdesivir and molnupiravir were effective against the BA.2 variant. Kawaoka’s research team found that AstraZeneca’s Evusheld was the most effective against the BA.2 variant out of the antibody treatments that were tested.
University Communications